Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 408

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 408
---
 subsidiaries who are not to continue as officers or directors of the Company or such subsidiaries; |

| • |     | since the Signing Date, no Material Adverse Effect will have occurred that is continuing; |

| • |     | the Concurrent Investment shall have been completed and the receipt of gross proceeds to TuHURA of not less than $20,000,000, which gross proceeds shall have been received by TuHURA, or will be received by TuHURA substantially simultaneously with the Closing; |

| • |     | the Company and (i) each holder of a Kineta Stock Option shall enter into an Optionholder Treatment Agreement and (ii) holders of each of the 2023 Company Warrants not automatically exercised or canceled pursuant to their terms immediately prior to the Effective Time of the Mergers, shall enter into a Warrantholder Treatment Agreement; |

| • |     | the Estimated Net Working Capital Deficit, if any, shall not exceed $6,000,000. |

| • |     | All of the members of the Kineta Board of Directors and Kineta’s executive officers including each of their affiliates which hold shares of Kineta Common Stock shall have executed and delivered lock-up agreements restricting the transfer, subject to certain exceptions, one-third of the shares of Kineta Common Stock received in the Initial Share Consideration; and |

| • |     | As of immediately prior to the Effective Time, the Company and its subsidiaries will have Program Assets, cash, cash equivalents, and prepaid expenses (and for the avoidance of doubt, will not have any material assets that are not Program Assets (“Non-VISTA Assets” ) and the completion of the disposition or dissolution of Kineta Chronic Pain, LLC, a Washington limited liability company and Yumanity, Inc., a Delaware corporation, will have occurred. |

249

In addition, under the Merger Agreement, the obligation of Kineta to effect the Mergers and otherwise complete the transactions contemplated by the Merger Agreement is subject to the satisfaction (or waiver by Kineta), at or prior to the closing, of each of the following conditions:

| • |     | the fundamental representations made by TuHURA in the Merger Agreement must be true and correct in all material respects both as of the Signing Date and as of the Closing Date, unless they are specifically made as of a different date; |

| • |     | the representations and warranties made by TuHURA in the Merger Agreement relating to certain capitalization and related matters were accurate in all